title: Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia.
abstract: BACKGROUND
  Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood. Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and to be particularly efficacious in treatment resistant cases of disorders such as schizophrenia.
  
  
  OBJECTIVE
  To test the a priori hypothesis that antipsychotic medications may differentially impact frontal lobe myelination in patients with schizophrenia.
  
  
  METHODS
  Participants ranged in age from 18-35 years, were all male, and were recruited by a single group of investigators using the same criteria. Two cohorts of subjects with schizophrenia early in their disease who were treated either with oral risperidone (Ris) or fluphenazine decanoate (Fd) were imaged in conjunction with cohorts of healthy controls. Each cohort was imaged using a different MRI instrument using identical imaging sequences.
  
  
  METHODS
  MRI measures of frontal lobe white matter volume.
  
  
  RESULTS
  We estimated differences due to differences in the MRI instruments used in the two studies in the two healthy control groups matched to the patient samples, adjusting for age and other covariates. We then statistically removed those differences (which we assumed were due to instrument effects) from the data in the schizophrenia samples by subtraction. Relative to the differences seen in controls, the two groups of schizophrenic patients differed in their pattern of frontal lobe structure with the Ris-treated group having significantly larger white matter volume than the Fd group.
  
  
  CONCLUSIONS
  The results suggest that the choice of antipsychotic treatment may differentially impact brain myelination in adults with schizophrenia. Prospective studies are needed to confirm this finding. MRI can be used to dissect subtle differences in brain tissue characteristics and thus could help clarify the effect of pharmacologic treatments on neurodevelopmental and pathologic processes in vivo.
authors.affiliation: Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1769, United States. gbar@ucla.edu
authors.forename: George
authors.initials: G
authors.lastname: Bartzokis
authors.forename: Po H
authors.initials: PH
authors.lastname: Lu
authors.forename: Keith H
authors.initials: KH
authors.lastname: Nuechterlein
authors.forename: Michael
authors.initials: M
authors.lastname: Gitlin
authors.forename: Clarissa
authors.initials: C
authors.lastname: Doi
authors.forename: Nancy
authors.initials: N
authors.lastname: Edwards
authors.forename: Christopher
authors.initials: C
authors.lastname: Lieu
authors.forename: Lori L
authors.initials: LL
authors.lastname: Altshuler
authors.forename: Jim
authors.initials: J
authors.lastname: Mintz
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005625:Frontal Lobe / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D009413:Nerve Fibers, Myelinated / Q000187:drug effects*; D012016:Reference Values; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; C011825:fluphenazine depot; D018967:Risperidone; D005476:Fluphenazine